US launches Section 301 tariff probe into German drug pricing policies
The United States has initiated a Section 301 trade investigation into Germany's pharmaceutical pricing policies, accusing Germany of "persistent underpayment" for innovative medicines that burdens American patients with disproportionate R&D costs. The probe targets German legislation to further reduce drug spending, which USTR Jamieson Greer called a "serious step backward." German Chancellor Friedrich Merz rejects the allegations, asserting national jurisdiction. The probe, which could lead to tariffs, is part of broader US efforts to equalize global drug prices, following a similar deal with the UK.
Cross-source coverage
Wire timeline
US Launches Patent Infringement Investigation into German Drug Price Controls
The Office of the US Trade Representative (USTR) has initiated a Section 301 investigation into Germany's pharmaceutical pricing and reimbursement policies, alleging persistent underpayment for innovative medicines and discriminatory practices against US commerce. The investigation, announced by USTR head Jamieson Greer, targets German reforms aimed at reducing spending on innovative drugs, including dynamic discounts on patent-protected medicines. The US argues it shoulders a disproportionate share of global R&D costs while European countries benefit from low prices. Potential outcomes include US tariffs or import restrictions on German goods, with broader implications for the EU. German Health Minister Nina Warken cited strained finances, while Chancellor Friedrich Merz faces domestic political pressure not to concede. Germany has offered talks but insists the matter is internal policy. The investigation is seen as a strategic move to pressure the largest EU pharmaceutical market, potentially triggering a domino effect across Europe.
Yahoo FinanceUS Launches Section 301 Patent Infringement Investigation into German Drug Price Controls
The Office of the US Trade Representative (USTR) has initiated a Section 301 investigation targeting Germany over its pharmaceutical pricing and reimbursement policies, which the Trump administration claims result in 'persistent underpayment for innovative medicines' and are discriminatory to US commerce. The probe, announced by USTR head Jamieson Greer, focuses on German reforms aimed at reducing spending on innovative drugs, including proposed dynamic discounts on patent-protected medicines. If violations are found, the US could impose tariffs or import restrictions on Germany, potentially escalating into broader EU trade tensions. German Health Minister Nina Warken cited a strained financial situation in the statutory health system, while Chancellor Friedrich Merz considers the issue an internal policy matter and has offered further talks. Germany is the largest EU pharmaceutical market, and the US hopes a concession could trigger a domino effect on other European nations.
Yahoo FinanceUS launches Section 301 probe into Germany over drug pricing policies
The U.S. Trade Representative (USTR) has initiated a Section 301 trade investigation into Germany's pharmaceutical pricing policies, alleging that Germany unfairly underpays for innovative drugs, forcing U.S. consumers to bear a disproportionate share of global R&D costs. The investigation, announced on June 18, 2026, focuses on a 2026 German draft law that would impose additional mandatory rebates on patented medicines, potentially reaching 20% by 2030. USTR Jamieson Greer stated that Germany must pay its fair share for pharmaceutical innovation, citing a 3.9 times price premium paid by U.S. consumers for brand-name drugs compared to German consumers. The probe follows a similar U.S.-UK arrangement that avoided tariffs, but experts warn that trade disputes often escalate beyond the initial industry. No tariffs have been announced yet, but the investigation could lead to trade actions. A public hearing is scheduled for September 22, 2026.
Yahoo FinanceUS Investigates German Drug Pricing as Unfair Trade Practice; Merz Rejects Allegations
The United States government has launched an investigation into German pharmaceutical pricing, accusing Germany of paying too little for innovative medicines. The probe aims to determine whether German pricing policies constitute an unfair trade practice. Former President Donald Trump has called for higher drug costs in Europe, arguing that the US subsidizes global pharmaceutical innovation. German Chancellor Friedrich Merz has rejected the allegations, defending Germany's pricing regulations. The dispute highlights ongoing transatlantic tensions over healthcare costs and trade imbalances. The outcome could affect drug pricing policies in both regions and impact the pharmaceutical industry globally.
Nachrichten - WELTU.S. opens Section 301 tariff probe targeting German pharmaceutical pricing policies
The United States Trade Representative (USTR) has launched a Section 301 investigation into Germany's pharmaceutical pricing policies, accusing the country of 'persistent underpayment' for innovative medicines. USTR Jamieson Greer stated that American patients should not bear a disproportionate share of global pharmaceutical R&D costs. The probe targets Germany's proposed legislation to overhaul its health insurance system, including higher discounts from the pharma industry, which Greer called 'a serious step backwards.' German Chancellor Friedrich Merz responded that the issue is a matter of national jurisdiction and expressed confidence the U.S. will abide by the EU trade agreement. The investigation could lead to tariffs on German goods. Greer suggested a negotiated solution modeled on the recent U.S.-U.K. deal, where the UK agreed to pay higher drug prices in exchange for tariff exemptions. The action is part of the Trump administration's broader 'Most Favored Nation' drug pricing policy aimed at reducing U.S. drug costs.
US Top News and AnalysisUS Opens Tariff Probe Targeting Germany's Drug Pricing Policies
The United States has initiated a Section 301 investigation into Germany's pharmaceutical pricing policies, alleging persistent underpayment for medicines that burdens American patients and undermines global R&D funding. U.S. Trade Representative Jamieson Greer expressed concern over Germany's fast-tracked legislation to further reduce spending on innovative drugs, calling it a 'serious step backward.' Germany, facing rising healthcare costs, proposed overhauling its health insurance system with cost-saving measures including higher discounts from pharma companies. Chancellor Friedrich Merz stated the issue falls under national jurisdiction and expressed confidence in existing EU-US trade agreements. The probe, authorized under the Trade Act of 1974, could lead to tariffs. Greer suggested a negotiated solution similar to the recent US-UK deal, where the UK agreed to higher drug prices in exchange for tariff exemptions. Critics warn that tying US drug prices to lower foreign prices risks stifling innovation and discouraging investment in new medicines.
US Top News and AnalysisUS launches trade probe into German drug pricing, escalating transatlantic tensions
The United States has initiated a Section 301 trade investigation into Germany over allegations of unfair drug pricing practices, escalating a transatlantic dispute. US Trade Representative Jamieson Greer announced the probe on Thursday evening, accusing Germany of fast-tracking legislation that would further reduce spending on innovative pharmaceuticals, burdening American patients with a disproportionate share of global R&D costs. The move follows months of talks between Washington and Berlin, with the US urging Germany to negotiate a deal similar to the UK's, which raised NHS prices for novel treatments by 25% in exchange for tariff cuts. Germany's Health Minister Nina Warken acknowledged financial constraints in the statutory health insurance system, complicating higher payments. The German pharma trade group vfa called for swift government talks to provide planning certainty. The EU defended the upcoming EU-US Joint Statement trade deal and expects the US to uphold commitments. The probe adds pressure on Germany's planned healthcare reforms, which include dynamic manufacturer discounts, opposed by companies like Pfizer.
EuractivU.S. launches Section 301 tariff probe into Germany's drug pricing policies
The United States has initiated a Section 301 investigation into Germany's pharmaceutical pricing policies, accusing the country of 'persistent underpayment' for innovative medicines. U.S. Trade Representative Jamieson Greer stated that American patients should not bear a disproportionate share of global pharmaceutical R&D costs, and criticized Germany's fast-tracked legislation to further reduce drug spending as 'a serious step backwards.' The probe follows Germany's April 2026 proposal to overhaul its health insurance system to curb rising healthcare costs, including higher discounts from the pharma industry. Several drugmaker executives have warned they might withdraw or delay new medicines in Germany as a result. The investigation allows the U.S. to take unilateral trade action if unfair practices are found. The German Health Ministry has not yet commented.
US Top News and Analysis